Oral Answers to Questions

Debate between Nick Thomas-Symonds and John Bercow

Thursday 2nd February 2017 Commons Chamber

[Mr Speaker]

The operative words are “public purse” and “fees”. Can we stick to that? It would be helpful.

[Nick Thomas-Symonds (Torfaen) (Lab)]

If the Government were genuinely motivated to spend this money by wanting a definitive answer from the courts on a constitutional question, why did they not thank the judges in the divisional court in November for such a clear answer, instead of being in a position where the Justice Secretary had to be pressured into giving a lukewarm defence of them?

Oral Answers to Questions

Debate between Nick Thomas-Symonds and John Bercow

Thursday 8th December 2016 Commons Chamber

[Nick Thomas-Symonds (Torfaen) (Lab)]

rose—

[Mr Speaker]

It is very good to see the hon. Gentleman back in his place.

[Nick Thomas-Symonds]

Thank you, Mr Speaker. The independent review commissioned by the Prime Minister that the Solicitor General has referred to expressed concern about the insufficient quality and quantity of intelligence at national, regional and international level, which it is said hampers our operational response. What steps does the Solicitor General think can be taken to ensure that our exit from the European Union does not further hamper our operational response?

Business of the House

Debate between Nick Thomas-Symonds and John Bercow

Thursday 20th October 2016 Commons Chamber

[Mr Speaker]

Order. What is needed now are questions in single short sentences. If those are forthcoming they will be heard; if not, they will not be.

[Nick Thomas-Symonds (Torfaen) (Lab)]

I associate myself with the remarks made about Aberfan and about my late friend and colleague Jo Cox.

On Saturday I will be attending the Remission Possible ball in honour of my young, inspirational constituent Emily Clark, who sadly died from cancer earlier this year. May we have a debate on the particular needs of young cancer patients when they suffer that terrible disease?

Oral Answers to Questions

Debate between Nick Thomas-Symonds and John Bercow

Thursday 14th April 2016 Commons Chamber

[Mr Speaker]

I hope that the Attorney General of all people will not underestimate the scope of his scholarly cranium, because the hon. Member for Kettering (Mr Hollobone) clearly does not do so.

[Nick Thomas-Symonds (Torfaen) (Lab)]

A condition of our membership of the European Union is that we are also a signatory to the European convention on human rights. Can the Attorney General confirm that this Government are committed to remaining a signatory to the convention and not to join Belarus, the only European country that is not a signatory?

Oral Answers to Questions

Debate between Nick Thomas-Symonds and John Bercow

Wednesday 13th April 2016 Commons Chamber

[Mr Speaker]

I think that the hon. Gentleman was referring to the Secretary of State for Defence, the right hon. Member for Sevenoaks (Michael Fallon). Some name was mentioned, but it does not mean anything in the Chamber.

[Nick Thomas-Symonds (Torfaen) (Lab)]

Since 2012, Jobs Growth Wales has helped 15,000 people into meaningful employment. Given that youth unemployment is falling faster in Wales than in the UK as a whole, does the Minister agree that the UK Government could learn from the Welsh Labour Government in this regard?

Access To Medical Treatments (Innovation) Bill

Debate between Nick Thomas-Symonds and John Bercow

Friday 29th January 2016 Commons Chamber

[Nick Thomas-Symonds (Torfaen) (Lab)]

I beg to move, That the clause be read a Second time.

[Mr Speaker]

With this it will be convenient to discuss the following:

New clause 2—Identifying evidence on off-patent repurposed drugs and passing to relevant bodies—

(1) The Secretary of State shall require the National Institute for Health Research to develop and introduce a mechanism for—

(a) gathering and recording existing evidence on off-patent, repurposed drugs, including clinical trial evidence, and

(b) passing this information to relevant bodies.

(2) The Secretary of State shall determine the relevant bodies under subsection (1) and may revise that determination from time to time.

New clause 3—Appraisal in new indications—

(1) Where there is an off-patent, repurposed drug with strong evidence of its effectiveness in a new indication, the Secretary of State shall direct the National Institute for Health and Care Excellence (NICE) to conduct an appraisal in relation to the drug in its new indication.

(2) An appraisal under subsection (2) should include a cost-effectiveness analysis.

New clause 4—National commissioning policy for off-patent new drugs—

Where there is an off-patent, repurposed drug with strong evidence of its effectiveness in a new indication, the Secretary of State shall require NHS England to produce and disseminate a national commissioning policy.

New clause 5—Accessibility of the licensing process—

(1) The Secretary of State shall require the Medicines and Healthcare products Regulatory Agency to consult key stakeholders about steps to be taken to make the licensing process more accessible to organisations or individuals other than pharmaceutical companies.

(2) For the purposes of subsection (1), key stakeholders shall include, but not be limited to—

(a) patient organisations,

(b) medical research charities,

(c) relevant academics, and

(d) the British Generic Manufacturers Association.

New clause 6—British National Formulary: inclusion of off-patent drugs—

The Secretary of State shall require NICE and the British National Formulary (BNF) to review their processes for registering off-label uses of repurposed drugs where there is strong evidence of their effectiveness.

Amendment 10, in clause 1, page 1, line 3, after “treatments” insert “(including treatments consisting in the off-label use of medicines or the use of unlicensed medicines)”

Amendment 13, in clause 5, page 3, line 44, at end insert—

“(1A) For the purposes of section 2(2), the kinds of medical treatment that may be innovative medical treatments include (amongst other things)—

(a) the off-label use of an authorised medicinal product, and

(b) the use of a medicinal product in respect of which no marketing authorisation is in force.

(1B) In subsection (1A)(a), the reference to the off-label use of an authorised medicinal product is a reference to the use of the product—

(a) for a purpose other than one for which its use is specified,

(b) in relation to a person who is not within a description of persons for whom its use is specified, or

(c) in any other way in which its use is not specified.

(1C) In this section—

(a) ‘authorised medicinal product’ means a medicinal product in respect of which a marketing authorisation is in force;

(b) ‘marketing authorisation’ and ‘medicinal product’ have the same meanings as in the Human Medicines Regulations 2012 (S.I. 2012/1916);

(c) ‘specified’, in relation to a medicinal product, means specified in its marketing authorisation.”

[Nick Thomas-Symonds]

These new clauses and amendments, which I support, relate to off-patent drugs. I think it would be useful for me briefly to set out the context in which they arise. The Off-patent Drugs Bill, a private Member’s Bill that I introduced—it was debated on Second Reading on 6 November—is a UK-wide Bill that would create a duty on the Government to make cheap drugs available when pharmaceutical companies had no incentive to do so. The problem, put simply, is that if a drug is shown to be useful for a new purpose after its original patent has expired, a pharmaceutical company has no financial incentive to sponsor that off-patent treatment through the processes normally used to license it and ensure its adoption on the NHS. Those off-patent or off-label treatments are certainly available at low cost. The issue is simply that although clinicians can of course prescribe them, they tend not to be prescribed consistently across the medical sector, or indeed geographically.

The Off-patent Drugs Bill ran out of time that day, but I think it is accurate to say that the Government supported its aims but not the mechanism it proposed. None the less, in recognising that there is a problem, and with a shared position on both sides of the House on the need to encourage greater consistency in off-label prescribing, a lot of work has since been done, and on a cross-party basis. I am proud that new clause 1 stands in the name of Members from no fewer than eight political parties. The concept of encouraging greater use of off-patent drugs, and indeed my Bill, have significant support across the House and outside. I pay tribute to Jonathan Evans, the former Member for Cardiff North, who first introduced such a Bill in 2014. His successor, the current Member for Cardiff North (Craig Williams), has also supported my Bill.